Surjit Dixit

Surjit Dixit is an experienced drug developer with an eye for creative application of structure guided rational molecular design technologies for multifunctional biologic drug optimization. Previously, he led the technical and scientific direction of the Zymeworks Inc for over 14 years where he served as CTO. He led the development of numerous technology platforms for Zymeworks including the AZYMETRIC™ bispecific platform which has been basis of multiple clinical candidates including Zanidatamab, the leading biparatopic antibody, which got its first FDA approval recently.

He is an inventor on over 26 patent families across areas of computational modeling, biologics design, and therapeutic drug candidates. He holds a Ph.D. in chemistry from the Indian Institute of Technology, New Delhi. ​